Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Medico Remedies's average EBITDA Per Share Growth Rate was 32.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 24.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 21.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medico Remedies was 50.70% per year. The lowest was 3.70% per year. And the median was 16.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Medico Remedies 5-Year EBITDA Growth Rate Related Terms
NSE:MEDICO vs ZTS: 5-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medico Remedies's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medico Remedies 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medico Remedies's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medico Remedies's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 24.20% mean?
Medico Remedies (NSE:MEDICO) has a 5-Year EBITDA Growth Rate of 24.20% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Medico Remedies and its competitors.
Is Medico Remedies' 5-Year EBITDA Growth Rate too high?
Medico Remedies' current 5-Year EBITDA Growth Rate is 24.20%. Overall, Medico Remedies has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medico Remedies' 5-Year EBITDA Growth Rate compare to ZTS?
Medico Remedies' 5-Year EBITDA Growth Rate of 24.20% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Medico Remedies and its competitors. Medico Remedies's current 5-Year EBITDA Growth Rate is 24.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medico Remedies stock overvalued right now?
Based on GuruFocus' analysis, Medico Remedies (NSE:MEDICO) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹77.84, compared to a current price of ₹34.89 — trading 55.2% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 24.20%. Medico Remedies' overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medico Remedies (NSE:MEDICO), the current 5-Year EBITDA Growth Rate is 24.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medico Remedies (NSE:MEDICO) Overvalued in 2026?
Based on GuruFocus' analysis, Medico Remedies stock appears to be undervalued.
The current stock price of ₹34.89 is trading 55.2% below its estimated GF Value™ of ₹77.84.
GuruFocus considers Medico Remedies to be Significantly Undervalued.
Key valuation signals for NSE:MEDICO:
5-Year EBITDA Growth Rate: 24.20%
GF Value™: ₹77.84 vs. price of ₹34.89 (55.2% below fair value)
No single metric tells the full story. See the NSE:MEDICO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medico Remedies Ltd is a manufacturer, supplier, and exporter of pharmaceutical drugs. It operates in single segment single segment of manufacturing medicines including Antihy pertensive Antidiabetics Antibictics Diuretics, Antimalarials, NSAIDS Tablets, Antireterovirals, Anti-Ulcer Drugs and Antacids Tablets, so many drugs used for treatment of so many diseases for oral use as well as external preparations like creams & ointments which includes anti infectives ,antifungals ,antibiotics ,steroidal preparations etc. In addition, it also sells other drugs such as antihistaminic, antidiabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and cream, and gel for various therapeutic segments.
81GF Score
Get the complete analysis for NSE:MEDICO
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDICO has been successfully added to your 
